Novartis AG Pharmaceutical, a Swiss Big Pharma company, is the manufacturer and distributor of Tasigna, a widely used cancer drug prescribed for chronic myeloid leukemia. With annual sales exceeding $2 billion in 2016, Tasigna has been found to cause a severe and rapid-onset form of cardiovascular disease known as atherosclerosis. Novartis has faced legal consequences for its illegal practices, including overcharges and fines, as well as allegations of hiding information about the increased risk of atherosclerosis from Tasigna usage.
Novartis AG Pharmaceutical, a multinational conglomerate, has a history of engaging in illegal activities to boost drug sales and has been fined by various authorities, including the United States Department of Justice and South Korea. Despite being aware of the link between Tasigna usage and atherosclerosis, Novartis allegedly failed to disclose this information to American users. Tasigna lawsuits have been filed against the company, seeking justice for individuals who have suffered from atherosclerosis, peripheral arterial disease, stroke, amputation, or death as a result of using Tasigna.
Generated from the website